Search
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalOtamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
Categories: Heterocyclic Compounds, 1-RingDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.
Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-AminopyridineDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalTwo denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides.
Categories: Complex MixturesProducts: PROLIA®, XGEVA® 120 MG/1.7 MLOfatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigationalOfatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. … has a higher affinity towards CD20.
Products: İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (3 ADET), İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (1 ADET)DiaPep 277
go.drugbank.com/drugs/DB06651InvestigationalDiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).
Categories: Group I Chaperonins, Diabetes Mellitus, Type 1Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSaredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitorsOdanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates